BIOMARKER IN INFLAMMATORY DISEASES
First Claim
Patent Images
1. A kit for diagnosing a disorder which is mediated by high levels of SPP2 or by SPP2 activity in a sample of an individual comprising:
- a) means for detecting the level of SPP2 in a sample;
b) instructions how to use said kit in dendritic cells;
c) a detection means; and
d) a solid phase.
0 Assignments
0 Petitions
Accused Products
Abstract
The use of SPP2 as a target in inflammatory responses, e.g. as a biomarker, e.g. for immune disorders associated with inflammation, such as psoriasis; diagnostic kits comprising means for determining the level of SPP2 and a method for identifying agents that modulates SPP2 activity.
-
Citations
10 Claims
-
1. A kit for diagnosing a disorder which is mediated by high levels of SPP2 or by SPP2 activity in a sample of an individual comprising:
-
a) means for detecting the level of SPP2 in a sample; b) instructions how to use said kit in dendritic cells; c) a detection means; and d) a solid phase. - View Dependent Claims (2, 3, 4)
-
-
5. A method for diagnosing a disorder which is mediated by high levels of SPP2 or by SPP2 activity, comprising the steps of:
-
a) providing a sample of an individual; b) determining the level of SPP2 in said sample; c) comparing the level of SPP2 as determined in step b) with a reference level; and d) diagnosing a disorder or disease, if the SPP2 level in the sample is elevated compared with the reference level. - View Dependent Claims (6)
-
- 7. A method of monitoring the therapeutic efficacy in the treatment of an individual with a substance which is expected to have an effect on reducing or curing a disorder which is mediated by elevated SPP2 levels or SPP2 activity, which method comprises the steps of determining the level of SPP2 in dendritic cells in a sample of said individual suffering from such disease and comparing the level determined with the level of SPP2 prior to administration of said substance.
-
9. An assay for identifying an agent that mediates a disorder which is mediated by elevated SPP2 levels or SPP2 activity, comprising the steps of:
-
a) determining the level of SPP2 in cells of a sample of an individual, in the absence and in the presence of a candidate compound which may be expected to modulate the level of SPP2; b) identifying a candidate compound which modulates the level of SPP2 as determined in step a) as an agent; and c) using such agent as a pharmaceutical in the treatment of disorders mediated by elevated SPP2 levels or SPP2 activity. - View Dependent Claims (10)
-
Specification